"4+7" with quantity procurement execution, linkage latest summary

Source: Minenet

Medical Network June 10th News On June 4th, the General Office of the State Council issued the key tasks of the medical reform in 2019, mentioned that it is necessary to solidly promote the pilot organization of centralized drug procurement and use by the state, and carefully summarize the pilot experience and push it forward in a timely manner. The first batch of “4+7” purchases were implemented for almost three months. From the implementation of the pilot cities in China and Xiamen and Chengdu, the overall progress exceeded expectations. At present, there are 9 non-"4+7" provinces and municipalities to take the initiative to follow up, and the volume of procurement is generally unstoppable, so where is the outlet for pharmaceutical companies?

At the State Council policy routine briefing held on April 16th, the deputy director of the National Medical Insurance Bureau said that as of the latest progress in centralized drug procurement, as of 24 o'clock on April 14, the total purchase of 25 selected varieties reached 438 million ( Piece/grain/branch), completed 27.31% of the total purchases. According to the medical cloud report, as of April 30, the total purchase of 25 selected drugs nationwide reached 599 million (pieces/grain/support), and the purchase amount was 794 million yuan, accounting for 37.32% of the total agreed purchase volume. The total purchase amount of unselected varieties reached 148 million (pieces/grain/support), and the total purchase amount was 857 million yuan. The selected varieties accounted for 80.21% of the total purchases of generic drugs, and the overall progress exceeded expectations.

As one of the “4+7” pilot cities, Xiamen opened its first drug selection prescription on March 18, becoming the first pilot city in the country. According to the Fujian Medical Insurance official micro-message, as of May 15, the total purchase volume of 25 selected varieties reached 12.67 million (pieces/pieces), and 59% of the agreed purchases were completed. The agreement purchases were in good condition. This means that since the selection of the varieties began to enter the hospital, in the past two months alone, Xiamen City has completed 60% of the amount.

Chengdu is also one of the “4+7” pilot cities. It is understood that as of 4:00 on May 26, the medical institutions in the region have sent a total of 1997 winning bids, with a total purchase volume of 52.408 million (pieces/grain/support). The total amount is 65.576 million yuan, accounting for 42.11% of the total contract volume of the city. The total purchase amount of unselected varieties was 11.3426 million pieces (pieces/grain/support), and the total purchase amount was 64.04 million yuan. The quantity and total amount of the selected varieties purchased accounted for 82.21% and 50.59% of the total quantity and total amount of the generic drug purchases, respectively.

In the early stage of “4+7” procurement, the industry was generally worried that the agreed purchase volume could not be guaranteed. However, from the current implementation situation, the overall progress exceeded expectations. In addition, it can be seen that the first batch of procurement, local It is still relatively conservative and prudent when reporting purchases, and this means that there is still room for further improvement in procurement quality and procurement efficiency.

In addition, from the implementation of the current pilot cities, the selected varieties accounted for more than 80% of the generic drug purchases, and the selected varieties replaced the non-selected varieties. The domestic generic drugs replaced the original research and were steadily advancing.

Three punches, "4+7" is fully unstoppable

More and more non-pilot cities have taken the initiative to follow up. The first batch of procurement execution results exceeded expectations. The second batch of pilot cities, varieties and purchases are expected to expand... "4+7" It’s already unstoppable!